Dr. Shin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
400 Shadow Lane
Suite 205
Las Vegas, NV 89106Phone+1 702-631-5000Fax+1 702-631-5002
Summary
- I am a board certified family physician and principal investigator conducting various multi-specialty clinical trials. I also have a non-profit clinic that helps the uninsured low-income families and homeless individuals.
Education & Training
In His Image at St John Medical CenterResidency, Family Medicine, 2000 - 2003
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 2000
Certifications & Licensure
FL State Medical License 2022 - 2025
NV State Medical License 2006 - 2025
TX State Medical License 2003 - 2007
OK State Medical License 2001 - 2003- American Board of Family Medicine Family Medicine
Clinical Trials
- Efficacy and Safety of Tolperisone in Subjects With Pain Due to Acute Back Muscle Spasm Start of enrollment: 2020 Dec 15
- Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I) Start of enrollment: 2019 Dec 30
Roles: Contact
- Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive Start of enrollment: 2022 Feb 17
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 58 citationsOnce-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, ...William O'Riordan, Carrie Cardenas, Elliot Shin, Alissa Sirbu, Lynne Garrity-Ryan
The Lancet. Infectious Diseases. 2019-10-01
Journal Articles
- Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, ...W O'Riordan, C Cardenas, E Shin, Lancet, 10/1/2019
Authored Content
- Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trialOctober 2019
Press Mentions
Doctor Treats Homeless for Free; Asks Patients to Pay It ForwardMarch 10th, 2020
Other Languages
- Korean
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
